. Author manuscript; available in PMC: 2017 Aug 22.

Published in final edited form as: Cancer. 2016 Sep 20;122(24):3765–3775. doi: 10.1002/cncr.30342

TABLE 3.

Recently Reported Negative Trials in Patients With Metastatic Pancreatic Cancer

Study	ClinicalTrials.gov Trial No.	Therapy	No.		Overall Survival, Months	Response Rate
ALPINE 2016⁷²	NCT01647828	GN ± OMP-59R5	177	OMP-59R5: notch 2/3 inhibitor
MAESTRO 2016⁷³	NCT01746979	Gemcitabine ± evofosfamide	693	Evofosfamide	7.6 vs 8.7 (P=.0589)	15% vs 19% (P=.18)
JANUS 1 and JANUS 2 2016⁷⁴	JANUS 1: NCT02117479 JANUS 2: NCT02119663	JANUS 1: ruxolitinib plus capecitabine JANUS 2: capecitabine ± ruxolitinib		Ruxolitinib: JAK 1/2 inhibitor
PANCRIT-1 trial 2016⁵	NCT01956812	Gemcitabine ± yttrium-90-labeled clivatuzumab tetraxetan		Yttrium-90-labeled clivatuzumab: monoclonal antibody targeting mucin conjugated with localized radiation

Abbreviations: GN, gemcitabine and nab-paclitaxel; JAK1/2, Janus kinase 1/2.